Latest news with #HCC
South Wales Argus
2 days ago
- Business
- South Wales Argus
Welsh lamb and beef to be promoted in New York
Hybu Cig Cymru – Meat Promotion Wales will promote the goods at the New York Summer Fancy Food Show, taking place from Saturday to Monday, to help strengthen trade links with America. Samples will be served and cooking demonstrations held while HCC and Welsh exporters will also take part in meetings and discussions. Jason Craig, HCC's market development lead, said: "Since the American market reopened several years ago, HCC has been working to develop trade in the market. "America is a market with large potential and we have seen small but significant growth in terms of trade volumes over the last couple of years." The USA reopened to UK beef exports in 2020 and to lamb in 2022, following the lifting of a 20-year ban. HCC, in partnership with the Welsh Government, will also host a 'Celebration of Welsh Lamb' event at the British Consulate in New York.
Business Wire
4 days ago
- Business
- Business Wire
MAIA Biotechnology Welcomes Leading Hepatocellular Carcinoma Clinician-Scientists to Scientific Advisory Board
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc. (NYSE American: MAIA) ('MAIA', the 'Company'), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced the appointment of two prominent oncologists to its Scientific Advisory Board (SAB), Claudia Fulgenzi, MD, and David J. Pinato, MD, MRCP (UK), PhD. Both are specialists in hepatocellular carcinoma (HCC), a tumor type to be studied in future clinical trials of MAIA's lead candidate ateganosine (THIO) sequenced with a checkpoint inhibitor. As SAB members they will advise MAIA on designs and protocols for its company sponsored trial (CST) in HCC and may participate in future investigator sponsored trials (IST). 'Drs. Pinato and Fulgenzi are scientific experts on inflammation as a pathogenic and prognostic mechanism in primary liver cancers. Together, their research has focused on improving the treatment of HCC, particularly with the use of anti-cancer immunotherapy,' said MAIA Chairman and CEO Vlad Vitoc, M.D. 'They will bring a wealth of knowledge to our SAB, with specialized expertise that will inform our plans and preparations for our upcoming clinical program in HCC. 'By the end of this year, we expect to have all required approvals to begin enrolling patients in a HCC trial,' Dr. Vitoc added. MAIA was granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for ateganosine as a treatment for HCC in 2022. ODDs can provide up to seven years of market exclusivity. Dr. David Pinato is a clinician scientist in the Department of Surgery and Cancer at Imperial College London and a consultant oncologist at Imperial College Healthcare NHS Trust. As Director of Developmental Cancer Therapeutics at Imperial College, he leads a translational research program focused on the early clinical implementation of novel experimental anticancer therapies with particular emphasis on anti-cancer immunotherapy. Dr. Pinato's research efforts in liver cancer have been recognized by the American Society of Clinical Oncology (ASCO) and the Society for Immunotherapy of Cancer (SITC). He has received awards by the British Society of Pharmacology and the Royal Society of Medicine, and fellowships by the European School of Oncology and Fulbright Program. Dr. Pinato completed his core medical training across some of the busiest acute hospitals in London and was elected to the Royal College of Physicians (MRCP). His research has been published in leading journals in the field including the Journal of Clinical Oncology, Annals of Oncology, Hepatology and many others. Dr. Pinato lectures internationally in the field of molecular oncology with a specific interest in HCC and acts as a reviewer for several peer-reviewed journals including The Lancet, Cancer Discovery, Hepatology and Journal of Hepatology. Dr. Claudia Fulgenzi is a specialist in medical oncology at Imperial College London, with dedicated professional interest in the field of immune-oncology and gastro-intestinal cancers, particularly hepatic-biliary malignancies. Dr. Fulgenzi graduated in medicine from the University of Rome Tor Vergata and subsequently specialized in medical oncology at the University Campus Bio Medico of Rome, Italy. Her contributions to the field have been recognized with prestigious awards including the ASCO Merit Award, the Young Investigator award by the International Liver Cancer Association (ILCA) and the American Society of Clinical Oncology. Dr. Fulgenzi is actively engaged in clinical practice in London, serving as an honorary consultant in oncology at Chelsea and Westminster Hospital and as a specialty doctor in the early phase clinical trial unit at Hammersmith Hospital. In these capacities, she conducts clinical and translational research, contributes to clinical trial design, and provides expert medical guidance to cancer patients. Hepatocellular carcinoma is the most frequently occurring primary liver tumor representing approximately 90% of all liver cancers. HCC currently ranks 5th by incidence and 3rd by mortality on a global scale. About Ateganosine Ateganosine (THIO, 6-thio-dG or 6-thio-2'-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical development to evaluate its activity in non-small cell lung cancer (NSCLC). Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. The modified nucleotide 6-thio-2'-deoxyguanosine induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. Ateganosine-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment of ateganosine followed by PD-(L)1 inhibitors resulted in profound and persistent tumor regression in advanced, in vivo cancer models by induction of cancer type–specific immune memory. Ateganosine is presently developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors. About MAIA Biotechnology, Inc. MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is ateganosine (THIO), a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit Forward Looking Statements MAIA cautions that all statements, other than statements of historical facts contained in this press release, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry's actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as 'may,' 'might,' 'will,' 'should,' 'could,' 'expect,' 'plan,' 'anticipate,' 'believe,' 'estimate,' 'project,' 'intend,' 'future,' 'potential,' or 'continue,' and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking. For example, all statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, are forward looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future events and are subject to risks and uncertainties and other factors beyond our control that may cause actual results to differ materially from those expressed in any forward-looking statement. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. In this release, unless the context requires otherwise, 'MAIA,' 'Company,' 'we,' 'our,' and 'us' refers to MAIA Biotechnology, Inc. and its subsidiaries.
Business Standard
4 days ago
- Business
- Business Standard
HCC MD & CEO Jaspreet Bhullar resigns
Hindustan Construction Company (HCC) announced that Jaspreet Bhullar has tendered his resignation from the position of managing director and chief executive officer (CEO) of the company, effective from 23 June 2025. Hindustan Construction Company is the flagship company of Hindustan Construction Company Group (HCC Group) and is involved in engineering and construction of infrastructure projects such as dams, tunnels, bridges, hydro, nuclear and thermal power plants, expressways and roads, marine works, water supply, irrigation systems and industrial buildings across the country. The company's consolidated net profit fell 63.4% to Rs 90.08 crore on a 22.5% drop in revenue from operations to Rs 1,373.70 crore in Q4 FY25 over Q4 FY24. Shares of Hindustan Construction Company rose 0.57% to Rs 30.25 on the BSE.
&w=3840&q=100)
Business Standard
5 days ago
- Business
- Business Standard
Hindustan Construction MD Jaspreet Bhullar resigns with immediate effect
Bhullar sent his resignation letter to company chairman Ajit Gulabchand in the afternoon, and the same was accepted by the board later in the day, as per an exchange filing The HCC scrip closed 1.02 per cent down at Rs 30.08 a piece on the BSE on Monday, as against a 0.62 per cent fall in the benchmark index. | File Image Press Trust of India Mumbai Hindustan Construction Company on Monday announced its managing director and chief executive Jaspreet Bhullar has quit with immediate effect. The company, however, did not disclose the reasons for the resignation. Bhullar sent his resignation letter to company chairman Ajit Gulabchand in the afternoon, and the same was accepted by the board later in the day, as per an exchange filing. "The Board ...has accepted his request for relieving him with effect from close of business hours of June 23, 2025," the filing said. Bhullar was appointed as the chief executive of the company in 2023 and given a five year term. He had joined the company from the Brookfield-run Multiplex Constructions India. The HCC scrip closed 1.02 per cent down at Rs 30.08 a piece on the BSE on Monday, as against a 0.62 per cent fall in the benchmark index.
Business News Wales
20-06-2025
- Business
- Business News Wales
Applications Open for Second Meat Minds Programme
The Meat Minds programme is now open for applications from people working in Wales' red meat supply chain. Launched last year, Hybu Cig Cymru – Meat Promotion Wales (HCC) said it had received an extremely positive response to the initiative and is on the look-out for its second group of recruits. Successful applicants will be given exclusive access to the latest industry insight and professional expertise during themed sessions and from a personal mentor. They will enjoy opportunities to develop their knowledge and understanding of all aspects of the supply chain, from farm to fork, and forge new connections. HCC's Producer and Processor Senior Officer Lowri Thomas said: 'We are pleased to offer this unique opportunity again this year to young and enthusiastic individuals. Members could be farmers, processors, butchers, retailers, chefs – or anyone involved in the red meat supply chain between the age of 21-35. They must be passionate about red meat production and promotion, interested in research and development and keen to see developments within the industry.' Participants will need to commit to a total of six days – five themed days and one other spent with an assigned mentor in the workplace. They will benefit from numerous networking opportunities and industry know-how from guest speakers. As a group, they will be expected to work collectively on an industry focused project of their choice to produce results that will benefit the industry. Lowri added: 'We have very much enjoyed working with a great group of people this year and look forward to providing the next group with a whole host of worthwhile experiences.' 2024-2025 group member Dafydd Walters said: 'We've had opportunities to meet people from within the sector and make valuable connections. We've heard from a dietician, we've touched on marketing, on nutrition, animal health and the environment, we've gained a real perspective of the red meat supply chain. The programme has been unique and a fantastic experience.' Daniel Owen is also a member of the first group. He said: 'We have met with several retail representatives as well as scientists and organisations that have taught us everything from farm to fork. The programme provides you with invaluable experience in the fact that you meet leaders within the industry and get to create connections with like-minded individuals your age.' The deadline to apply for the second round of Meat Minds is 5pm on Wednesday 2 July. The application form can be downloaded from the HCC website.
